Medicine in Practice, Inc. is excited to announce the launch of its first product - a website named TipTopTitles to support efficient conduct and publication of biomedical researchYardley, PA (PRWEB) June 14, 2012 Many biomedical researchers struggle to publish their research. Part of the problem is lack of time, but a significant contributor is lack of familiarity with what is an increasingly ...
Read the original here:
PLANEGG, Germany--(BUSINESS WIRE)--
Within the last year Biomax Informatics has established the knowledge integration platform in a research project to develop a new generation of healthcare tools for predictive, personalized medicine. The Synergy-COPD project, funded by the European "Framework Programme 7", will generate a simulation environment and clinical decision support system enabling systems medicine. Though generally applicable, the tools created will be validated using data from patients with chronic obstructive pulmonary disease (COPD). The project's goal is to improve patient care and healthcare outcomes, reduce errors and increase efficiency.
Leveraging Biomax's BioXM technology, a comprehensive COPD knowledge base with a graphical frontend for visualizations is being established. The system integrates five well-established simulations of human physiology with biomedical data drawn from experimental studies, epidemiological data, clinical trials, physician interviews, a multi-center longitudinal study on COPD phenotyping, and public datasets. Integrating with a Simulation environment, researchers will be able to perform simulations linking symptoms and pathologies in organs and tissues with other features, such as metabolic pathways. Building on this foundation, a decision support system will allow doctors to anticipate disease progression and optimize therapy.
COPD was chosen to validate the projects systems biology approach because it is a complex, heterogeneous, multi-component disease. COPD is also a major public health problem: it is ranked as the fourth leading cause of death in Europe and one of Europe's leading causes of healthcare costs. "COPD is the ideal target for this project, which aims to realize patient-centered, integrated medicine in general healthcare," says Dr. Dieter Maier, Biomax Project Manager. "Our aim is to equip healthcare providers with innovative tools that lead to the best treatments for patients."
About the Synergy-COPD project
The Synergy-COPD project is funded by the European Union's Seventh Framework Programme for Research and Technological Development (FP7) to develop a simulation environment and a decision-support system enabling systems medicine. The project's research partners are leading experts in the field of COPD and relevant technologies and methods for advancing COPD research. More information about the consortium is available at http://www.synergy-copd.eu.
About Biomax
Biomax Informatics AG (Planegg, Germany), founded in 1997, is a leader in the development of computational solutions for the life sciences. Biomax developed the BioXM Knowledge Management Environment and markets the Viscovery technology for better decision-making and knowledge management in biomedical sciences. More information about Biomax is available atwww.biomax.com.
See the original post here:
Biomax Informatics AG Reaches First Milestone in European Systems and Personalized Medicine Project
HUNTSVILLE, Ala.--(BUSINESS WIRE)--
ADTRAN, Inc. (ADTN), a leading provider of next-generation networking solutions, today announced that Family Medicine of Port Angeles (FMPA) has joined the growing number of healthcare providers that have turned to ADTRANs NetVanta Unified Communications Notification Server (UCNS) to help it manage outbound client call flow. The NetVanta UCNS system enables FMPA to conduct, in their case, up to 200 appointment call reminders daily, and allows patients to reschedule appointments in real-time if necessary. This information has proved invaluable to FMPA as it knows in advance if changes are made to the next days schedule so they can plan accordingly.
ADTRANs NetVanta solution has already had a tremendous positive impact on our firm as it frees up staff time to better manage other aspects of our practice, said Kelly Steed, FMPAs IT administrator. Weve gone from a task that would have taken hours to complete if we had the time and resources, to a simple, easy-to-use process that I can set up in a few minutes each day. With this solution deployed, we now have a predictable, reliable notification system that is helping staff and our patients keep on top of their busy schedules.
The NetVanta UCNS provides FMPA the flexibility to send appointment reminders by phone via its out-dialing capabilities of NetVanta UC or by email, enabling it to contact patients based on their own personal preferences filed in a patient information database. FMPA is using its NetVanta UCNS in conjunction with ADTRANs NetVanta 7100 voice and data platform for a comprehensive VoIP communications system. This combination of technologies will provide FMPA with the modularity and flexibility needed to scale their UC programs as the practice grows to handle new patients and expand into new offices.
Now in use by hundreds of healthcare providers and other businesses around the country, ADTRANs UCNS has become the de facto standard for automated client communication programs, said Barry Derrick, ADTRANs Product Marketing Manager, Enterprise Networks Division. The appeal is driven by the systems performance, ease-of-use, scalability and ability to have our customers redeploy valuable employee resources to other activities.
About ADTRAN
ADTRAN, Inc. is a leading global provider of networking and communications equipment, with a portfolio of more than 1,700 solutions. ADTRANs products enable voice, data, video and Internet communications across a variety of network infrastructures. ADTRAN solutions are currently in use by service providers, private enterprises, government organizations and millions of individual users worldwide.
For more information, contact the company at 800 9ADTRAN (800 923-8726) or via e-mail at info@adtran.com. On the Web, visit http://www.adtran.com.
Read more here:
Family Medicine of Port Angeles Dials In ADTRAN for Intelligent Unified Communications
SALT LAKE CITY--(BUSINESS WIRE)--
Alliance Health Networks, the leading social networking company serving consumers and the healthcare industry, today announced its sponsorship of 35 ePatient scholarships for the 2012 Medicine X conference at the Stanford University School of Medicine. The scholarships, granted by Medicine X, provide the funds needed for these ePatientshighly informed and engaged patients who make significant use of online resources to track and manage their healthto attend the 2012 Medicine X conference in September.
Medicine X is a catalyst for new ideas about the future of medicine and healthcare, and is designed to explore the potential of social media and information technology to advance the practice of medicine, improve health, and empower patients to be active participants in their own care. The Medicine X conference aims to bring a broad academic approach to understanding emerging technologies with the potential to improve health and advance the practice of medicine.
Medicine X is an academic conference designed for everyone, said Dr. Larry Chu, associate professor of anesthesia at Stanford and executive director of the conference. And, through our scholarship program, 10 percent of the seats are being given for free to patients. We hope this will unite patients with healthcare providers, researchers and technologists to solve healthcare problems.
Alliance Health sponsored the ePatient scholarship program to help bring an active patient voice to the Medicine X conference. The company owns and operates more than 50 specific social health networks such as Diabetic Connect, Heart Connect, Sleep Connect and Arthritis Connect, among others that connect more than 1.5 million registered patients and caregivers to each other and to valuable condition-specific information.
The ePatient perspective is critical when exploring the new shape of healthcare, and Alliance Health is thrilled to provide the means for these 35 individuals to lend their voices to the conversation, said Stead Burwell, CEO of Alliance Health Networks. As a health-based social engagement platform, we know firsthand that people are using social networks to manage their health journey in ways that were never imagined even just a few years ago. We are happy to partner with Stanford Medicine X to help propel this important healthcare discussion forward.
Applicants for the scholarship had to demonstrate a history of patient engagement, community outreach and advocacy, with a preference given to individuals using emerging technologies such as blogs, Twitter, and social media to pursue these goals. Scholarship recipients will have the opportunity to participate both as attendees and speakers, and will also be given the chance to contribute to a patient-centered design project facilitated by the health and wellness team at the international design firm IDEO.
Under the direction of Chu, Medicine X is a project of the Stanford AIM (Anesthesia Informatics and Media) Lab. The 2012 Medicine X Conference will be held September 28-30.
About Alliance Health Networks
Alliance Health Networks is building a free and independent social engagement platform that gives people the power to navigate their personal health journey. The company owns and operates more than 50 social networks and 20 mobile versions serving over 1.5 million registered members. Alliance Health leverages social networks to help consumers more actively manage their care through personal connections, powerful tools, and deeper insights. The company's investors include New World Ventures, Physic Ventures, Highway 12 Ventures, and EPIC Ventures. For more information, visit: http://www.alliancehealthnetworks.com.
Here is the original post:
Alliance Health Networks Announces Sponsorship of 35 Stanford Medicine X ePatient Scholarships
11-06-2012 09:51 David Stein, MD, associate professor and chief of colorectal surgery at Drexel Medicine discusses the importance of creating a "Partnership in Caring" between physicians and patients. Stein's focus includes the laparoscopic treatment of colorectal cancer and inflammatory bowel disease. He is board certified in both general surgery and colorectal surgery. He sees patients in Center City Philadelphia and Wilmington, Delaware. His physician profile can be located here: To make an appointment with Dr. Stein, please call 1-866-DREXEL 2; or log onto http://www.drexeldoctors.com.
Continued here:
Drexel Medicine Surgeon Discusses the Importance of Patients
12-06-2012 11:17 ~Used 2008 GMC Sierra 1500 All Terrain GFX~Wow is this a nice truck!!~This All Terrain comes with a 5.3L V8, cloth interior, rainsense wipers, 4x4, front buckets, 18" chrome wheels, power fold mirrors, dual zone climate, is GM Optimum Certified, and more!~2 years free maintenance a Davis GMC Buick Exclusive~Proudly Serving Medicine Hat, Brooks, Lethbridge, Calgary, Edmonton, Fort McMurray, Swift Current, Regina, and Saskatoon. Email Tony at for more information! Search all our used inventory at;
Continue reading here:
Used 2009 GMC Sierra 1500 All Terrain GFX | Davis GMC Buick | Medicine Hat Alberta - Video
Newswise The American College of Veterinary Internal Medicine (ACVIM) and the International Veterinary Information Service (IVIS) are working together to educate veterinarians, veterinary students, technicians and those involved in animal health about the importance of research and curing diseases in animals, and in promoting their organizations as sources of education and information.
ACVIM and IVIS both have educational resources available for veterinary professionals, many for free. ACVIM offers continuing education programs through its annual ACVIM Forum Conference, Advanced Education Courses at the Oquendo Center, consensus statements and other online resources. Topics at this years Forum event included:
Controversies in Mitral Valve Disease in Dogs Equine Metabolic Syndrome Management of Resistant Bacterial Infections Biomarker Development for Canine Degenerative Myelopathy Parasite Resistance in Camelid, Small Ruminant, and Cattle The New Grading Scheme for Canine Mast Cell Tumors
The IVIS website provides free access to original, up-to-date e-books, proceedings of veterinary meetings, journals, reviews, an international calendar of veterinary events and much more, with the help of private and corporate sponsors. Learn more about IVIS at http://www.ivis.org.
ACVIM and IVIS have come together to help educate veterinarians, animal owners and the general public by providing them with resources so they can learn about specialty medicine, said Leah Cohn, ACVIM board of regents chairman. The ACVIM is committed to leading our profession by continuing to provide educational resources for our Diplomates, Candidates and other veterinary professionals.
About International Veterinary Information Service (IVIS) International Veterinary Information Service (IVIS) is a not-for-profit organization established in 1998 in Ithaca NY by academic faculty from veterinary colleges and veterinary research institutes in North America and Europe. The IVIS website (www.ivis.org) provides a convenient way to access information on Veterinary Medicine including authoritative original and reprinted e-books and the proceedings of many national and international specialty conferences. IVIS is available as a free service, supported by sponsors and readership donations. It is open to the entire veterinary community including veterinary students, after a brief on-line registration at http://www.ivis.org. IVIS also provides quick-links to journal articles, an extensive calendar of veterinary meetings, special topic reviews and white papers, and translations into as many as 12 different languages, and much more. Come visit the IVIS website http://www.ivis.org. Access is free.
About the American College of Veterinary Internal Medicine (ACVIM) ACVIM is the national certifying organization for veterinary specialists in large and small animal internal medicine, cardiology, neurology and oncology. Established in 1973, ACVIMs purpose is to advance the knowledge of animal health and diseases, and to foster the continued development of specialty veterinary care. To find an ACVIM Specialist in your area, please visit http://www.ACVIM.org.
# # #
Read more from the original source:
MIAMI--(BUSINESS WIRE)--
Data presented at the Society for Nuclear Medicine (SNM) Annual Meeting shows that uptake of the investigational imaging agent [18F]flutemetamol correlates with a beta amyloid in vivo1 biopsy and can be quantified using a PET-only registration method.2 Data from other studies show that [18F]flutemetamol uptake is inversely related to measures of cognitive function in non-demented older adults3. Additionally, the [18F]flutemetamol dosimetry profile is comparable to that of most PET diagnostic radiopharmaceuticals4 and the biodistribution attributes in Japanese and Caucasian subjects is comparable. 5 [18F]Flutemetamol is a PET imaging agent in development for the detection of beta amyloid, which could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions like Alzheimers disease (AD).
The accumulation of beta amyloid in the brain is believed to play a role in the degeneration of neurons in AD and is one of several pathological characteristics implicated in its development. Currently, AD is confirmed by histopathological identification of core features, including beta amyloid plaques, in postmortem brain samples.6Targeted amyloid imaging agents are being studied to determine their ability to help physicians detect amyloid deposition in living humans.
Data from studies featured at the meeting in Miami show that:
Flutemetamol may prove to be a clinically valuable component of a broader diagnostic workup that neurologists use when assessing patients with cognitive impairments, who possibly have Alzheimers disease, said Jonathan Allis, General Manager, PET, GE Healthcare, Medical Diagnostics. Results from these studies support the potential role of [18F]flutemetamol in helping physicians detect amyloid deposits in the brain, and support our application for regulatory approval.
[18F]Flutemetamol is one part of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimers field. The company is taking a comprehensive approach to understanding AD through its ongoing research to uncover the causes, risks, and physical effects of the disease. GE Healthcares global commitment to advance clinical knowledge and provide a variety of technologies to aid in the fight against this epidemic may assist physicians in the acceleration of diagnosis and improvement of treatment decisions in all stages of the disease.
The company already offers a broad portfolio of imaging resources, which support accurate visualization of the signs of neurodegenerative diseases via state-of-the-art scanners - including MRI, PET, and CT - that deliver clear visualization of the brain.More specifically, our portfolio today includes cyclotrons and chemistry systems to manufacture PET imaging agents, PET and MR scanners to scan patients, and image analysis software to interpret the results.
GE Healthcare has been a key contributor to the Alzheimers Disease Neuroimaging Initiative (ADNI) since its inception. The company also plays a primary role in PredictAD, an EU-funded research project to develop solutions to enable earlier diagnosis of AD, and in the Coalition Against Major Diseases (CAMD).
Additionally, the combination of GE Healthcares diverse business offerings positions the company well to offer an integrated global diagnostics solution to assist the pharmaceutical industry in its development of the next generation of therapies. To that end, the company is working with potential partners in the pharmaceutical industry to understand their strategic needs and design solutions, and help provide imaging support for pivotal therapy trials.
ABOUT GE
Here is the original post:
PHILADELPHIA A new report issued today by the American College of Cardiology (ACC) and developed in collaboration with 10 other leading professional societies provides detailed criteria to help clinicians maximize the appropriate use of certain noninvasive vascular tests when caring for patients with suspected or known non-coronary arterial disorders. Emile R. Mohler, MD, professor of Medicine and director of Vascular Medicine at Penn Medicine, chaired the national committee producing the criteria.
"This is the first systematic and comprehensive evaluation looking at appropriate indications for vascular testing, such as ultrasound or functional testing," said Dr. Mohler, who is also a member of the Penn Medicine Cardiovascular Institute. "We hope this document will help clinicians determine whether or not and when to refer individual patients for testing."
Ultrasound and other noninvasive laboratory tests can be essential tools to help clinicians evaluate vascular blockages and disease, for example, in the arteries of the neck, kidneys, abdomen, and lower extremities, as well as the aorta itself. Such testing also plays a central role in surveillance of the vascular system in some patients to help inform treatment decisions and prevent serious problems, and is part of follow-up after peripheral vascular procedures, such as arterial bypass, surgical removal of plaque (endarterectomy), or stenting. Still, guidance about when and how to best use this technology in practice is largely missing, according to experts.
Such decisions affect a growing number of patients as the population ages. Dr. Mohler estimates more than 20 million adults in the U.S. have some form of vascular disease, and would likely be a candidate for these types of tests.
The panel identified common clinical scenarios when noninvasive vascular testing might be considered in patients with suspected or known non-coronary arterial disorders (e.g., narrowing or blockages in the arteries of the neck, kidneys, abdomen or legs, abdominal aortic aneurysms, arterial dissection). Applying a rigorous rating scale, the 19-member panel then assessed the appropriateness of each indication and often at different time intervals (3-5, 6-8 and 9-12 months).
In addition to looking at the reasons for ordering these tests, the work group also sought to determine how frequently repeat testing is needed in clinical practice in light of the need for ongoing surveillance in some patients.
The appropriate use criteria were developed in collaboration with the ACC, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society of Interventional Radiology, Society for Vascular Medicine and Society for Vascular Surgery. The document is further endorsed by the American Academy of Neurology, American Podiatric Medical Association, Society for Clinical Vascular Surgery, Society for Cardiovascular Magnetic Resonance, and Society for Vascular Ultrasound.
For more information on the new guidelines, please see the ACC press release.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Here is the original post:
MORRISVILLE, N.C.--(BUSINESS WIRE)--
Geomagic, a global company providing 3D technology solutions for digital reality, today announced it will showcase best practices and output from its customers digital orthopedic product workflows at this weeks OMTEC 2012 event in Chicago beginning Wednesday, June 13th. As orthopedic implant manufacturers work to apply the latest technologies to their patient-specific implant processes, Geomagics customers demonstrate the results that are made possible when medicine meets 3D capture, touch-enabled design, 3D inspection and digital manufacturing technology.
Speakers and exhibits at OMTEC 2012 will depict the use of Geomagics products in the latest materials for the ultimate in personalized fit, form and function. For example, Level 3 Inspections Bill Greene will outline the advantages of Computer Aided Inspection for orthopedic implants as a way to deliver better patient-specific forms, faster, with fewer iterations, less waste, and lower cost. Bill will be presenting at the conference on Thursday June 14, at 10 am CT.
Geomagic will be demonstrating its Freeform Modeling System for organic design and preparing files for manufacturing. Level 3 Inspection also will join Geomagic and demonstrate its scanning solution using Geomagic Qualify for inspection and analysis.
Advanced software is allowing us to solve clinical problems we couldnt even begin to touch before, and Geomagics solutions are at the heart of the innovation, said Barry Fell, president of Thermoplastic Products Corp. in Hummelstown PA, who designs and prototypes custom orthopedic implants.
By using Geomagics suite of 3D solutions, including Geomagic Studio to capture real world data, Freeform to develop designs, and Geomagic Qualify to inspect and check manufactured products, medical manufacturers are moving to successful mass custom manufacturing through 3D digital reality. Innovative orthopedic products created using Freeform, Geomagic Studio and Geomagic Qualify on display at OMTEC include:
Digital reality, like the digital economy, is a fact of life today, allowing art and science, and in this case medicine, to achieve breakthrough results that are not possible without our technology, said Ping Fu, CEO of Geomagic. A good example is the use of additive manufacturing in exciting new ways. What was previously utilitarian, and perhaps cast or vacuum formed with standard parts, now can be designed more elegantly, ergonomically and aesthetically and printed in new bio-compatible materials. Its a new era for the practitioners and patients in the orthopedic industry.
Geomagic is exhibiting in booths 831-833 at OMTEC, which takes place at the Donald E. Stephens Convention Center, 5555 North River Road in Chicago, on Wednesday June 13 from 9 am 6 pm CT, and Thursday June 14 from 9 am 12 noon CT.
About Geomagic
Geomagic (www.geomagic.com) is a global company dedicated to advancing and applying 3D technology for the benefit of humanity. Different from CAD, Geomagic offers specific products to create 3D content from imaging the real world and real people, verify dimensional quality by comparing a master design to as-built products, and simulate touch sensations in digital environments. Products include Geomagic Studio, Geomagic Qualify, Geomagic customers are the most innovative companies in industries ranging from aerospace, automotive, toys, moldmaking, medical device, surgical simulation, consumer products, arts, heritage, research and education. Some of the leading companies around the globe using Geomagic products include Ford, BMW, Boeing, Harley Davidson, Timberland, Fisher Price, Lego, Pratt & Whitney, NASA, Schneider Electronic, 3M, Danaher and Invisalign. Geomagic is based in Research Triangle Park, NC, USA, with an office in Boston and subsidiaries in Europe and Asia, and channel partners worldwide.
See the original post:
Geomagic Demonstrates How Medicine Meets 3D at OMTEC 2012 Event
HOLLYWOOD, Calif., June 11, 2012 /PRNewswire/ -- Medicine Dispensing Systems, Inc., a subsidiary of Medbox, Inc., (MDBX) (www.medboxinc.com) has successfully completed and filed 110 applications for the granting of medical marijuana dispensing licenses for its consulting clients in the State of Arizona. The company completed the lengthy and complicated process on behalf of groups and individuals that are seeking to open dispensaries in Arizona's tightly regulated market.
Neither Medicine Dispensing Systems nor Medbox, Inc. own any marijuana dispensing clinics. The company acts as a consultant and helps guide those wishing to open a clinic through the complex issues that regulate the medical marijuana industry, and the steps that are necessary to operate in full compliance of each individual States regulations. The company has become nationally recognized as a leader in obtaining positive outcomes in the application process due to their comprehensive suite of services, which includes in-depth consultations, securing special zoning permits, handling lease negotiations, and specifying specialized clinic equipment.
The company also provides their patented Medbox Dispensing System, which is the most secure and transparent method to assure patient verification and compliance with all state and local regulations. The system, whether by machine or the company's POS system, is currently in use by over 100 clinics nationwide, and provides assurance to state regulators that clinics are being operated legitimately, legally, and in accordance with all rules governing these types of clinics.
Arizona voters approved a Measure in 2010 that allows certain qualifying patients to obtain medical marijuana from a registered dispensary. The Arizona Department of Health Services accepted dispensary applications from May 14 thru May 25, 2012.
The DHS received 484 dispensary applications for 126 possible dispensaries. The state allows a maximum of one dispensary per each of the State's 126 Community Health Analysis Areas (CHAAs). Arizona, with its forward-thinking regulations and seed to sale transparent tracking is looking to be the gold standard for future States as they navigate ways to allow their citizens access to medical marijuana without creating a detriment to the community. According to Will Humble, Arizona's Department of Health Services Director, the DHS expects to award the Dispensary Certificates on August 7.
"Our company is focused on States that have polished regulations concerning medical marijuana. States like Arizona and now Connecticut are setting a proper example for other States moving forward that have learned a lesson from less organized States like California and Colorado. The numbers of medical marijuana clinics should be based on population density and awarded by the State, in a tightly regulated system," stated Dr. Bruce Bedrick, CEO of Medbox, Inc. "Policies need to be crafted on a State level at the onset in order for these clinics not to cause a nuisance on communities."
About Medbox, Inc:
Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Medbox has offices throughout the world, including New York, Tokyo and Toronto, and has their corporate headquarters in Los Angeles.
Medbox provides their patented systems, software and consulting services to pharmacies, urgent care centers, clinics, hospitals, and medical groups worldwide.
Medbox, Inc. is a publicly traded company, and is listed on the OTC Board, ticker symbol MDBX.
Read more here:
SAN DIEGO, June 11, 2012 /PRNewswire/ --
Shire plc, the global specialty biopharmaceutical company, announced today that its Regenerative Medicine business, Advanced BioHealing, Inc., has entered into a lease agreement with BioMed Realty Trust, Inc. which will allow the company to further expand its operational footprint and presence in the San Diego area over the next several years.
The new campus will provide Shire's Regenerative Medicine business the increased capacity it needs to meet future demand for its lead product, DERMAGRAFT, while offering additional space and infrastructure to manufacture new regenerative medicine products, in alignment with the business' strategic growth plan.
"We are committed to investing in and expanding our Regenerative Medicine business and with the signing of this lease, we are pleased to confirm and build our presence in San Diego with BioMed Realty as our real estate partner," said Kevin Rakin, Shire's Regenerative Medicine President. "This new campus will give us the flexibility and increased capacity we need to develop and manufacture new regenerative medicine therapies and build our foundation for continued growth in this exciting field."
Phase I of the site development will be in excess of 150,000 square feet and will house the company's manufacturing and associated support operations, commercial operations, corporate, and administrative functions. This expansion could create several hundred local jobs once the regenerative medicine campus is operational.
"Shire's commitment to growing its Regenerative Medicine business in San Diego is important to a region where one-in-10 people remain unemployed," said Congressman Brian Bilbray (CA-50). "This investment will not only provide additional opportunities for rewarding, high-paying jobs, but will ensure that San Diego remains a leader in the development of innovative patient care."
Shire expects to begin construction of the new campus in Sorrento Mesa in 2013, with initial occupancy targeted for 2014.
"We are pleased to enter into this partnership with Advanced BioHealing, which is the culmination of extensive, collaborative efforts by both companies to identify and execute on a real estate solution which will fully support their development and manufacturing needs," said Alan D. Gold, Chairman and Chief Executive Officer of BioMed Realty. "We look forward to working closely with the Advanced BioHealing and Shire teams to develop this future multi-phase campus for the development and commercialization of important regenerative medicine therapies."
The company plans to maintain its current DERMAGRAFT manufacturing facility on North Torrey Pines Road in La Jolla, CA, which currently employs nearly 200 people.
Read more:
Shire's Advanced BioHealing Commits to Developing Regenerative Medicine Campus in San Diego
MIAMI--(BUSINESS WIRE)--
West Kendall Baptist Hospitals new Family Medicine Center is now open, providing area residents with high-quality primary and preventive care. West Kendall residents can now turn to the Baptist Health Medical Group Family Medicine Center at West Kendall Baptist Hospital for all routine care needs, such as physical examinations (including school physicals), flu and allergy shots, non-emergency illnesses and injuries and chronic disease management.
The opening of the Family Medicine Center is the next step toward our goal of creating a comprehensive healthcare community here, said Javier Hernndez-Lichtl, CEO of West Kendall Baptist Hospital. Residents already turn to us for inpatient care, surgeries, emergencies and childbirth. Now we can serve their day-to-day care needs, as well, for the entire family.
The Family Medicine Center, conveniently located on the first floor of the hospitals Medical Arts Building, is designed to promote a vision of providing leading practices in education and compassionate care in a high-tech and high-touch environment. The state-of-the-art facility includes six private exam rooms, on-site laboratory, group meeting room, teleconference center and wireless computer tablets for patient registration. The Center will serve patients of all ages, including pediatric and geriatric patients.
"West Kendall residents are welcome to call and arrange a tour, said Agueda Hernndez, M.D., medical director of the Family Medicine Center. Our staff will be here to welcome you and assist in setting up your new care relationships and transferring records.
Staff physicians include Dr. Hernndez and Manuel Torres, M.D. They have admitting privileges at West Kendall Baptist Hospital as well as other facilities in the Baptist Health South Florida network. The Family Medicine Center will also function as the primary training ground for the West Kendall Baptist Hospital Family Medicine Residency Program, in affiliation with Florida International Universitys Herbert Wertheim College of Medicine, which will launch in the summer of 2013.
The Family Medicine Center is located in the Medical Arts Building adjacent to West Kendall Baptist Hospital, 15955 SW 96 Street. Regular office hours are 9 a.m. to 5 p.m., Monday through Friday. Most major forms of health insurance are accepted. For more information or to make an appointment, call 786-467-3140.
Since opening its doors in April 2011, West Kendall Baptist Hospital personnel have treated more than 30,000 patients in its emergency room, and welcomed more than 200 babies at the Beautiful Beginnings Family Birthing Suites. Other notable awards include becoming the first acute-care hospital in Florida to earn LEED Gold certification for its environmentally conscious facilities and practices, and ranking as the #1 Most Beautiful Hospital in Florida and fourth most beautiful nationwide.
About West Kendall Baptist Hospital
The newest member of the not-for-profit Baptist Health South Florida family, West Kendall Baptist Hospital is a LEED Gold-certified, patient- and family-centered facility serving one of South Floridas most vibrant, youthful and fast-growing communities. Beginning in 2013, the hospital will be home to an accredited family practice residency program through its affiliation with Florida International Universitys Herbert Wertheim College of Medicine. To learn more, visit WestKendallBaptistHospital.com.
Follow this link:
Family Medicine Center Brings New Primary and Preventive Care Options to West Kendall
June 10, 2012
MINNEAPOLIS (AP) -- A new study that measured the financial impact of veterinary medicine in Minnesota finds it contributes $1.5 billion annually to the state's economy.
The report from the University of Minnesota Extension and Department of Applied Sciences attributes that figure to the economic activity generated by an estimated $680 million in annual combined wages and salaries of 14,500 people employed in the state's veterinary medicine industry.
The study found 10 of Minnesota's 87 counties do not have a private veterinary practice. Those practices account for the bulk of the veterinary workforce, employing 7,700 people in Minnesota with $550 million in salaries and wages.
The state Board of Animal Health; the Minnesota Zoo; and the state Departments of Health, Agriculture and Natural Resources employ 97 veterinarians and generate $24 million in economic activity.
Read the original post:
Americans are increasingly looking for ways to improve their health and well-being.
If you're like others, you may consider your mental and spiritual health to be equally as important as your physical health. Alternative medicineor nontraditional health caremay meet your needs by caring for both the physical and spiritual aspects of your life.
What is alternative medicine? Alternative medicine is a holistic or whole mind/body approach to health care that complements, rather than competes with, conventional medicine. When diagnosing and treating a patient, an alternative medicine practitioner considers not only the patient's physical health, but his or her mental and spiritual condition as well. Many different alternative treatments exist, including some that are becoming accepted by practitioners of traditional medicine:
Should you use alternative medicine? People who use alternative medicine often believe that good health is not just the absence of diseaseit also means being physically, mentally, and spiritually fit. You may decide to use alternative medicine if you believe that:
What is the difference between conventional and alternative medicine? Conventional and alternative medicines share the same goalthey seek to cure patients. However, they go about treating the patient's symptoms differently. Alternative medicine will often stimulate the body's natural recuperative powersthe immune systemto assist in the healing process. Alternative medicine is more apt to treat with natural substances such as zinc.
Conventional medicine often uses medications that have an immediate impact on the patient's symptoms. These are often manufactured drugs containing synthetic chemicals. The side effects of these medications can be more severe than those of alternative medications.
Alternative medicine often works best when combined with conventional medicine. In some cases, you may have little choicealthough alternative medicine may work well over time, your condition may require immediate treatment, and more conventional methods of medicine may be your only option.
Is alternative medicine really safe? Although it may seem like alternative medicine is a recent development, it has actually been around for longer than conventional medicine. Many of the medications and practices considered nontraditional today have their roots in traditional African, American, Asian, and European medicine. Because of their widespread popularity overseas, some alternative medications used in the United States may have already been tested abroad.
Many alternative medicinesand many alternative treatmentsdon't receive official approval from the Food and Drug administration or conventional medical community because their effects are hard to quantify. Conversely, these same medications and treatments are usually not as dangerous or invasive as more conventional treatments.
Here are some commonsense ways to make using alternative medicine safer:
View post:
Everything You Ever Wanted To Know About Alternative Medicine
MIAMI, June 8, 2012 /PRNewswire/ --At this year's SNM Annual Meeting, June 9-13, Royal Philips Electronics (NYSE: PHG, AEX: PHI) is highlighting its portfolio of nuclear medicine (NM) applications for IntelliSpace Portal, adding to its existing portfolio of CT, MR and multimodality applications. The full suite of NM applications will now offer comprehensive processing and review capabilities at a level normally reserved exclusively for dedicated NM workstations. The company will also showcase solutions designed to increase diagnostic confidence, enhance patient comfort, augment physician confidence, simplify clinical workflow and reduce lifecycle costs.
To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/philips-demonstrates-innovations-in-nuclear-medicine-imaging-with-a-comprehensive-portfolio-of-nm-applications-for-intellispace-portal-157951125.html
"The nuclear medicine applications portfolio for the IntelliSpace Portal is designed to help nuclear medicine professionals improve their workflow and evaluate a patient's progress," said Jay Mazelsky, senior vice president and general manager, Philips Computed Tomography and Nuclear Medicine. "As a leader in nuclear medicine, Philips strives to provide solutions for our customers that improve collaboration in order to provide enhanced care for patients."
The NM applications portfolio for IntelliSpace Portal now allows NM technologists and physicians to process, review and analyze images from SPECT, SPECT/CT, PET/CT and PET/MR, and then share images and findings with referring physicians using advanced collaboration tools. The clinical applications on IntelliSpace Portal can be accessed from virtually any networked computer allowing clinicians the flexibility to collaboratively assess results at the hospital or remotely.
"The IntelliSpace Portal nuclear medicine features have drastically changed the way we treat patients," said Janusz Kikut, MD, director of nuclear medicine and PET/CT, Fletcher Allen Health Care, Burlington, Vt. "The features now allow us to better monitor change in disease status using the nuclear medicine imaging modalities that are often important to diagnosis. And, since we can access IntelliSpace Portal away from our campus, we've been able to improve our workflow with radiologists and seamlessly communicate the nuclear medicine results to referring physicians."
Since the IntelliSpace Portal is built on a scalable server-client platform, it also offers the flexibility to efficiently add concurrent users as well as new clinical applications. This virtually eliminates the need for costly and time consuming upgrades across multiple workstations. The IntelliSpace Portal can also interface with Philips or non-Philips picture archiving and communication systems (PACS), providing direct access to the comprehensive suite of NM review and processing applications.
Key NM application features include:
Philips is a leader in nuclear medicine imaging and delivers advanced solutions that meet the challenges clinicians often face. In addition to IntelliSpace Portal, Philips will also feature:
About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 122,000 employees with sales and services in more than 100 countries worldwide. With sales of EUR 22.6 billion in 2011, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at http://www.philips.com/newscenter.
Here is the original post:
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Foundation Medicine today announced a new agreement with Novartis to provide comprehensive genomic analysis in support of Novartis clinical oncology programs.
Novartis plans to use Foundation Medicines molecular information platform across many of Novartis Phase 1 and 2 oncology clinical programs. The pilot program established between Novartis and Foundation Medicine 18 months ago has generated very interesting data, and this type of tumor genomic profiling has become an essential component of Novartis clinical trials. The partnership consists of running Foundation Medicines comprehensive genomic profiling on most Phase 1 and 2 clinical trial enrollees over the next three years. The partnership aims to accelerate the development of Novartis broad portfolio of targeted cancer therapeutics and ultimately expand treatment options for patients.
The comprehensive molecular assessment of Novartis Oncology clinical trial samples is expected to help to bring potentially lifesaving therapies to the right patients more quickly, and we expect that the wealth of molecular information will help fundamentally improve the way cancer is understood and treated, said Michael J. Pellini, M.D., president and CEO, Foundation Medicine. We are pleased to see our collaboration mature into a significant relationship between Foundation Medicine and Novartis.
Foundation Medicine uses clinical-grade, next-generation sequencing to rapidly analyze hundreds of cancer-related genes from formalin-fixed, paraffin-embedded tumor samples in a CLIA-certified environment. Novartis plans to use these capabilities in an effort to align clinical trial enrollment and outcome analysis with the genomic profile of individual patient tumors to drive development of new cancer treatments. Foundation Medicine also offers testing services to physicians and their patients through the companys commercial product, FoundationOne, which includes an interpretive report that matches detected genomic alterations with potential treatment options and clinical trials. The company may develop additional diagnostic products resulting from the Novartis collaboration.
About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys initial clinical product, FoundationOne, is a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.foundationmedicine.com.
See more here:
Somewhere around 25 percent of doctors practicing in this country have been trained at medical schools outside the United States (a good percentage are from India, the Philippines, Mexico, Pakistan and the Dominican Republic).
Some of these foreign-trained doctors grew up in foreign countries. Others are American citizens who were not able to find a spot in a U.S. medical school and decided to go abroad for medical training.
Collectively, these foreign-trained doctors are far more likely to practice in less desirable specialties like internal medicine, psychiatry and family medicine, and they are far more likely to practice in physician-short areas like the inner city or rural America.
They are more likely to care for poor patients, charge less money for a visit and work longer hours than American-trained physicians. There are studies suggesting that the quality of care these foreign-trained doctors provide is at least as good as that provided by the average American doctor.
Bottom line is that without these foreign-trained doctors, we as a nation would be in big trouble providing our citizens with health care.
Yet, too often foreign-trained doctors are ostracized and treated as second class citizens both by American-trained doctors and by patients. Foreign-trained doctors may speak with an accent, and some may be difficult to understand.
It is not uncommon to hear a patient tell the hospital clerk that they only want to see an "American doctor" and sometimes the language they use is even uglier when they make this request. I understand that people have prejudices, they have fears, and when they go to the doctor they are sick but these assumptions can be counterproductive.
A foreign accent does not mean poor medical training. Some of the very best doctors I've worked with have been trained outside of North America. Admittedly, medical schools outside the U.S. vary considerably, and there are some absolutely rotten schools. But there are many foreign schools that provide the same excellent level of training that is provided by American schools. Unfortunately, our American medical schools also train some poor doctors. After all, someone has to graduate at the bottom of the class, right?
In many areas, such as in the ability to do a comprehensive physical examination or to understanding the underlying science behind medicine, foreign-trained students surpass American students. However, there is one common area where foreign medical schools fall short and that is in the area of preparing doctors for the culture, communication and ethics required to practice in the United States.
As patients, Americans expect their doctors to listen to them and explain their condition so that they as consumers can participate in making medical decisions. Americans expect doctors to be honest with them and tell them the truth even when the news is bad news. In many countries, such approaches to medical care are not routine and are not taught. But foreign-trained doctors are smart men and women, and they learn Americanisms quickly.
Continue reading here:
New studies highlighting the promise of individualized, precision medicine were released recently at a press briefing at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).
These studies demonstrate that we are solidly in the era of precision medicine, in which patients benefit from a growing understanding of cancers genetic weak spots, said news briefing moderator Sylvia Adams, MD, Assistant Professor in the Department of Medicine at New York University Langone Medical Center. Todays findings promise to expand the range of effective, targeted treatments for people with cancer. They also affirm that patients in all settings, from research hospitals to smaller community institutions, can expect to benefit in the years ahead.
Key study findings include:
Media Resources:
About ASCO The American Society of Clinical Oncology (ASCO) is the worlds leading professional organization representing physicians who care for people with cancer. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For more information, visit http://www.asco.org/presscenter. Patient-oriented cancer information is available atwww.cancer.net.
SOURCE: The American Society of Clinical Oncology (ASCO)
Read this article: